LIEBERMAN GERALD M 4

What Happened

• Gerald M. Lieberman, a director of Teva Pharmaceutical Industries Ltd. (TEVA), reported conversion/exercise of derivative awards on June 5, 2026. The filing shows 14,492 shares were acquired on exercise/conversion and the same 14,492 shares were disposed at $0.00. No cash proceeds or per-share prices are reported for the acquisition; the disposal is recorded at $0.00.

Key Details

• Transaction date: 2026-06-05; SEC filing date: 2026-06-08 (filing appears timely).
• Transaction code: M (exercise or conversion of derivative security).
• Shares acquired: 14,492; Shares disposed: 14,492; Reported disposal price: $0.00.
• Shares owned after the transaction: not specified in the provided filing data.
• Relevant footnotes:
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
  • F2: Each restricted share unit (RSU) represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one share.
  • F3: These RSUs were granted on June 5, 2025 and vested on June 5, 2026.

Context

• The filing reflects RSUs vesting and converting to ordinary shares. The simultaneous disposition recorded at $0.00 (as shown in the filing) often reflects shares withheld or otherwise surrendered to satisfy withholding or settlement obligations, though the filing does not specify the reason. This is not an open-market purchase or sale of shares; it documents settlement of an equity award.